TY - JOUR
T1 - Prognostic Value of [F-18]-Fluoromethylcholine Positron Emission Tomography/Computed Tomography Before Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer
AU - Cysouw, Matthijs
AU - Bouman-Wammes, Esther
AU - Hoekstra, Otto
AU - van den Eertwegh, Alfons
AU - Piet, Maartje
AU - van Moorselaar, Jeroen
AU - Boellaard, Ronald
AU - Dahele, Max
AU - Oprea-Lager, Daniela
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Purpose: To investigate the predictive value of [F-18]-fluoromethylcholine positron emission tomography/computed tomography (PET/CT)-derived parameters on progression-free survival (PFS) in oligometastatic prostate cancer patients treated with stereotactic body radiation therapy (SBRT).Methods and Materials: In [F-18]-fluoromethylcholine PET/CT scans of 40 consecutive patients withResults: Thirty-seven lymph node and 13 bone metastases were treated with SBRT. Thirty-three patients (82.5%) had 1 lesion, 4 (10%) had 2 lesions, and 3 (7.5%) had 3 lesions. After a median follow-up of 32.6 months (interquartile range, 35.5 months), the median PFS was 11.5 months (95% confidence interval 8.4-14.6 months). Having more than a single metastasis was a significant prognostic factor (hazard ratio 2.74; P=.03), and there was a trend in risk of progression for large MATV (hazard ratio 1.86; P=.10). No SUV or total lesion choline uptake was significantly predictive for PFS, regardless of partial-volume correction. All PET semiquantitative parameters were significantly correlated with each other (PConclusions: The number of choline-avid metastases was a significant prognostic factor for progression after [F-18]-fluormethylcholine PET/CT-guided SBRT for recurrent oligometastatic prostate cancer, and there seemed to be a trend in risk of progression for patients with large MATVs. The lesional level of [F-18]-fluoromethylcholine uptake was not prognostic for progression. (C) 2018 Elsevier Inc. All rights reserved.
AB - Purpose: To investigate the predictive value of [F-18]-fluoromethylcholine positron emission tomography/computed tomography (PET/CT)-derived parameters on progression-free survival (PFS) in oligometastatic prostate cancer patients treated with stereotactic body radiation therapy (SBRT).Methods and Materials: In [F-18]-fluoromethylcholine PET/CT scans of 40 consecutive patients withResults: Thirty-seven lymph node and 13 bone metastases were treated with SBRT. Thirty-three patients (82.5%) had 1 lesion, 4 (10%) had 2 lesions, and 3 (7.5%) had 3 lesions. After a median follow-up of 32.6 months (interquartile range, 35.5 months), the median PFS was 11.5 months (95% confidence interval 8.4-14.6 months). Having more than a single metastasis was a significant prognostic factor (hazard ratio 2.74; P=.03), and there was a trend in risk of progression for large MATV (hazard ratio 1.86; P=.10). No SUV or total lesion choline uptake was significantly predictive for PFS, regardless of partial-volume correction. All PET semiquantitative parameters were significantly correlated with each other (PConclusions: The number of choline-avid metastases was a significant prognostic factor for progression after [F-18]-fluormethylcholine PET/CT-guided SBRT for recurrent oligometastatic prostate cancer, and there seemed to be a trend in risk of progression for patients with large MATVs. The lesional level of [F-18]-fluoromethylcholine uptake was not prognostic for progression. (C) 2018 Elsevier Inc. All rights reserved.
KW - ANDROGEN DEPRIVATION THERAPY
KW - METASTASIS-DIRECTED THERAPY
KW - OF-THE-LITERATURE
KW - F-18-FLUOROCHOLINE PET/CT
KW - C-11-CHOLINE PET/CT
KW - FREE SURVIVAL
KW - RECURRENCE
KW - RADIOTHERAPY
KW - GUIDELINES
KW - PARAMETERS
U2 - 10.1016/j.ijrobp.2018.02.005
DO - 10.1016/j.ijrobp.2018.02.005
M3 - Article
SN - 0360-3016
VL - 101
SP - 406
EP - 410
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 2
ER -